Allison Beck

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 12 papers. Top paper: “Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria”.

Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria

New England Journal of Medicine(2022)10.1056/nejmoa2203067

N/A

3.6DataRank · unranked

125 citations

Azza H. Idris, Nina M. Berkowitz, Myra Happe, Martin R. Gaudinski, Christian Buettner +42 more

An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults

Science Translational Medicine(2023)10.1126/scitranslmed.ade4790

N/A

1.9DataRank · unranked

96 citations

Amelia R. Hofstetter, Katherine V. Houser, Seemal F. Awan, Grace Chen, Maria Claudia Burgos Florez +95 more

Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial

The Lancet Infectious Diseases(2022)10.1016/s1473-3099(22)00052-4

N/A

1.1DataRank · unranked

39 citations

Srilatha Edupuganti, Grace Chen, Myra Happe, Larisa Strom, Alicia T. Widge +67 more

Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial

The Lancet Infectious Diseases(2023)10.1016/s1473-3099(23)00344-4

N/A

1.0DataRank · unranked

24 citations

Katherine V. Houser, Amelia R. Hofstetter, Ana M. Ortega‐Villa, Prossy Naluyima, Francis Kiweewa +70 more

Dose-Response of a Norovirus GII.2 Controlled Human Challenge Model Inoculum

The Journal of Infectious Diseases(2022)10.1093/infdis/jiac045

N/A

0.543DataRank · unranked

13 citations

Allison Beck, Amy Kirby, Pengbo Liu, Muktha S. Natrajan, Lilin Lai +19 more

Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guérin Challenge Model for Assessment of Tuberculosis Immunity In Vivo

The Journal of Infectious Diseases(2023)10.1093/infdis/jiad441

N/A

0.390DataRank · unranked

9 citations

Rachel L. Edwards, Mei Xia, Christopher S. Eickhoff, Fahreta Hamzabegovic, Krystal A. Meza +20 more

Safety and pharmacokinetics of N6LS, a broadly neutralising monoclonal antibody for HIV: a phase 1, open-label, dose-escalation study in healthy adults

The Lancet HIV(2025)10.1016/s2352-3018(25)00041-4

N/A

0.335DataRank · unranked

8 citations

Katherine V. Houser, Martin R. Gaudinski, Alicia T. Widge, Seemal F. Awan, Cristina Carter +95 more

An Oil-in-Water adjuvant significantly increased influenza A/H7N9 split virus Vaccine-Induced circulating follicular helper T (cTFH) cells and antibody responses

Vaccine(2022)10.1016/j.vaccine.2022.09.041

N/A

0DataRank · unranked

0 citations

Nadine Rouphael, Yongxian Xu, Sarah Kabbani, Allison Beck, Amy C Sherman +6 more

Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine

npj Vaccines(2024)10.1038/s41541-024-00959-0

N/A

0DataRank · unranked

21 citations

Amelia R. Hofstetter, Pamela Costner, LaSonji A Holman, Cynthia S. Hendel, Alicia T. Widge +95 more

Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials

npj Vaccines(2024)10.1038/s41541-024-00833-z

N/A

0DataRank · unranked

19 citations

Amelia R. Hofstetter, Jing Wang, Galina V. Yamshchikov, LaSonji A. Holman, Laura Novik +93 more

Dose-Response of a Norovirus GII.2 Controlled Human Challenge Model Inoculum

UNC Libraries(2024)10.17615/41dn-ky49

N/A

0DataRank · unranked

0 citations

Natrajan M.S, Jill El-Khorazaty, Nadine Rouphael, Kirby A.E, Collins M.H +19 more

Duration of Cellular and Humoral Responses after Quadrivalent Human Papillomavirus Vaccination in Healthy Female Adults with or without Prior Type 16 and/or 18 Exposure

Vaccines(2020)10.3390/vaccines8030348

N/A

0DataRank · unranked

5 citations

Kevin A. Ault, Nadine Rouphael, Allison Beck, Briyana Domjahn, Yongxian Xu +13 more